Zhaoke Ophthalmology recently announced positive topline results from Mini-CHAMP, the one-year Phase III trial for its NVK002 myopia drug.  This news coincided with an update from the company’s US partner Vyluma on the positive outcome of its own study.  Together, these results make a powerful combination and bring Zhaoke one step closer to submitting a New Drug Application to the Chinese regulator.  In this podcast, the company’s Chief Financial Officer and Chief Business Officer, Lisa Feng, discusses the study results as well as their significance for Zhaoke and for the treatment of myopia in children.